Therapeutics

Pimavanserin

Overview

Name: Pimavanserin
Synonyms: Nuplazid, ACP-103, Pimavanserin tartrate
Therapy Type: Small Molecule (timeline)
Target Type: Other Neurotransmitters (timeline)
Condition(s): Alzheimer's Disease, Schizophrenia, Dementia, Depression
U.S. FDA Status: Alzheimer's Disease (Phase 3), Schizophrenia (Phase 3), Dementia (Phase 3), Depression (Discontinued)
Company: Acadia Pharmaceuticals
Approved for: Parkinson's psychosis

Background

Pimavanserin is a serotonergic agent, specifically a selective serotonin (5-HT) 2A receptor inverse agonist. In April 2016, the FDA approved this once-daily atypical antipsychotic to treat the delusions and hallucinations that are a feature of psychosis in Parkinson's disease, and it came on the market in the United States in June (April 2016 newsprescribing information). Pimavanserin is thought to have fewer adverse effects than older antipsychotic agents used to treat Parkinson's psychosis, but evidence remains limited (e.g., Sarva and Henchcliffe, 2016Tampi et al., 2019).

The drug carries a black-box warning of increased mortality in elderly people. One large study reported a higher risk of death in nursing home residents with PD who were prescribed pimavanserin (Hwang et al., 2021), while other analyses found no extra risk (Moreno et al., 2018; FDA analysis).

Pimavanserin affects heart rhythms, and should not be used by people with arrhythmia or who take drugs that prolong the QT interval. The most common adverse events seen in trials were peripheral edema, nausea, confusion, hallucinations, constipation, and gait disturbance, though Acadia argues that PD with psychoses itself is associated with a higher risk of falls (Forns et al., 2021). Phase 4/real-world trials in Parkinson's psychosis are ongoing (Dashtipour et al., 2021Cusick and Gupta, 2021).

Pimavanserin is in development for psychosis, agitation, and aggression in Alzheimer's disease. It is also in development for schizophrenia, depression, insomnia, PTSD, and for psychosis related to all-cause dementia. A different serotonin 2A receptor inverse agonist, nelotanserin, was in Phase 2 development for dementia with Lewy bodies (DLB) but has been discontinued.

Serotonin receptor activation is known to inhibit brain amyloid-β peptide production by altering the cleavage of amyloid precursor protein (see Sheline et al., 2014). In recent preclinical work, pimavanserin or another 5HT2A agonist, M100907, acutely reduced Aβ concentrations in brain interstitial fluid of APP/PS1 transgenic mice. Chronic administration to aged APP/PS1 mice decreased CSF Aβ and brain plaque pathology, and improved cognition (Yuede et al., 2021Gründer and Cumming, 2021).

Findings

Between November 2013 and November 2016, Acadia conducted a Phase 2 study of pimavanserin in 181 nursing home residents in London, who had psychosis along with their clinical diagnosis of AD. Participants received a 12-week course of 40 mg pimavanserin or placebo, and were evaluated on the nursing home version of the neuropsychiatric inventory (NPI), the short form of the Cohen-Mansfield Agitation Inventory (CMAI-SF), and the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC). The primary outcome was change from baseline to six weeks in the NPI-NH, where lower scores mean fewer symptoms. By two weeks, both the placebo and pimavanserin groups had improved on the test. At six weeks, those taking the drug had a 39.5 percent reduction in NPI-NH scores, compared to 19.3 percent reduction in the placebo group. However, by 12 weeks, scores were down 40 percent from baseline in both groups. These results were presented at CTAD, and later formally published (Dec 2017 conference newsBallard et al., 2018). A subsequent subgroup analysis claimed a larger treatment benefit in participants with more severe psychosis (Ballard et al., 2019). Another post hoc analysis reported that people who responded to pimavanserin with a 50 percent or greater reduction in psychotic symptoms also improved on measures of agitation and aggression (Ballard et al., 2020).

In November 2016, Acadia started SERENE, a Phase 2 study comparing the effect of 34 mg and 20 mg pimavanserin to placebo in people with agitation and aggression as part of their Alzheimer's disease, on the CMAI-SF as primary outcome. This trial anticipated enrolling 432 patients at 56 sites, but stopped randomizing patients in November 2017 and was marked as complete in March 2018, with 111 patients enrolled and 83 of them having completed treatment. In March 2019, the trial's status was further updated to "terminated." Results, as well as sponsor rules restricting principal investigators from discussing and publishing results, are published in the clinicaltrials.gov History of Changes section of this trial. At 111 actual participants, the trial was underpowered to detect a treatment effect. The SERENE trial had a one-year open-label extension study, which recruited 79 patients and ended in February 2019.

From 2017 to 2019, Acadia conducted a Phase 3 study at 101 study locations in the U.S., Europe, and Chile, to evaluate pimavanserin’s efficacy in preventing psychosis relapse in people who had previously responded to the drug. The HARMONY trial enrolled 392 participants with all-cause dementia who had had symptoms of psychosis for at least two months. In an initial, 12-week open-label phase, all participants took 34 mg pimavanserin with the option to drop to 20 mg. The 217 who responded with a decrease in psychotic symptoms continued into a 26-week double-blind period, in which they were randomized to pimavanserin or placebo. The primary endpoint was delay in psychosis relapse with a p value below 0.0033. Relapse was defined as hospitalization due to dementia-related psychosis, significant deterioration of dementia-related symptoms on clinical scales, withdrawal from the study due to lack of efficacy, or use of an off-label antipsychotic medication. Patients were followed until relapse occurred (Cummings et al., 2018). According to a company press release, an interim analysis indicated that this trial met its primary endpoint early, and the trial was stopped (Sep 2019 news). Trial results published after peer review reported that 13 percent of the pimavanserin group relapsed, compared to 28 percent in the placebo group (Tariot et al., 2021). Of the participants, 66 percent had Alzheimer’s, 15 percent had Parkinson’s, and the remainder had vascular dementia, dementia with Lewy bodies, or frontotemporal dementia. Common treatment-related adverse events were urinary tract infection, headache, and constipation. QT interval prolongation occurred in 1.3 percent of pimavanserin-treated people. The types of side effect commonly associated with antipsychotics were infrequent.

In May 2018, Acadia started enrolling 300 people who had neuropsychiatric symptoms along with a neurodegenerative disease into a Phase 3 safety study, to be conducted at 116 sites in Europe, Asia, and North and South America. It is enrolling patients living at home or in assisted living. The study compares the effect of an eight-week course of 34 mg pimavanserin to placebo on treatment-emergent adverse events, extrapyramidal symptoms, and the MMSE. In October 2019, the enrollment was increased to 750. The study is scheduled for completion in August 2022 and has a long-term extension going through August 2023.

In June 2020, based on data from the HARMONY dementia trial, Acadia submitted a supplemental new drug application to the FDA for pimavanserin to treat hallucinations and delusions in people with dementia-related psychosis (press release). On April 5, 2021, the company announced that the agency had declined to approve, citing a lack of substantial evidence of effectiveness. The FDA reportedly noted the absence of statistically significant changes in some of the dementia subgroups, and low numbers of patients with less common dementia subtypes (press release). According to Acadia, the decision was unexpected, given that the FDA had previously approved the study design, which analyzed people with different types of dementia as a single group, and met its primary endpoints (company slides). The FDA also rejected results from the SERENE Alzheimer’s trial as supporting evidence, saying the single-center study was not adequate and well controlled.

A meta-analysis of safety outcomes in four placebo-controlled trials, presented at CTAD 2020, indicated that the drug causes no cognitive decline. In people treated with pimavanserin for up to nine months, changes in MMSE scores were small and similar to placebo. Of 14 cognition-related adverse events, confusional state and memory impairment were reported in all four studies, and occurred in fewer than 2 percent of patients. Pimavanserin did not affect motor function.

For all trials of pimavanserin, see clinicaltrials.gov.

Last Updated: 15 Sep 2021

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

News Citations

  1. Pimavanserin Trial Raises Hope for Treating Dementia-Related Psychosis
  2. Phase 3 Trial Suggests Pimavanserin Assuages Psychosis in Dementia
  3. Pimavanserin Nears Approval to Treat Psychosis in Parkinson’s

Therapeutics Citations

  1. Nelotanserin

Paper Citations

  1. . Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018 Mar;17(3):213-222. PubMed.
  2. . Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. J Prev Alzheimers Dis. 2019;6(1):27-33. PubMed.
  3. . Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. Int J Geriatr Psychiatry. 2020 Nov;35(11):1402-1408. Epub 2020 Aug 25 PubMed.
  4. . Pimavanserin: Potential Treatment For Dementia-Related Psychosis. J Prev Alzheimers Dis. 2018;5(4):253-258. PubMed.
  5. . Trial of Pimavanserin in Dementia-Related Psychosis. N Engl J Med. 2021 Jul 22;385(4):309-319. PubMed.
  6. . Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis. Ther Adv Neurol Disord. 2016 Nov;9(6):462-473. Epub 2016 Oct 3 PubMed.
  7. . Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatry. 2019 Jun 10;9(3):47-54. PubMed.
  8. . Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology. 2021 Sep 28;97(13):e1266-e1275. Epub 2021 Aug 13 PubMed.
  9. . Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021;16(1):e0246121. Epub 2021 Jan 27 PubMed.
  10. . Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice. Parkinsons Dis. 2021;2021:2603641. Epub 2021 Jan 4 PubMed.
  11. . Pimavanserin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 Apr 30.
  12. . An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014 May 14;6(236):236re4. PubMed.
  13. . Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease. J Neurochem. 2021 Mar;156(5):658-673. Epub 2021 Jan 10 PubMed.
  14. . Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease. J Neurochem. 2021 Mar;156(5):560-562. Epub 2021 Jan 18 PubMed.

External Citations

  1. press release
  2. press release
  3. company slides
  4. clinicaltrials.gov
  5. prescribing information
  6. Moreno et al., 2018
  7. FDA analysis

Further Reading

Papers

  1. . Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers. Mini Rev Med Chem. 2016 Oct 24; PubMed.
  2. . Differential effects of angiotensin II receptor blockers on Aβ generation. Neurosci Lett. 2014 May 1;567:51-6. Epub 2014 Mar 27 PubMed.
  3. . Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies. PLoS One. 2016;11(5):e0155823. Epub 2016 May 17 PubMed.
  4. . Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015 Mar;65(3):651-61. Epub 2015 Jan 12 PubMed.
  5. . [Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer's disease]. Zhonghua Yi Xue Za Zhi. 2012 Oct 23;92(39):2743-6. PubMed.
  6. . Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull. 2012;35(12):2141-7. PubMed.
  7. . Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. Curr Psychiatry Rep. 2019 Aug 8;21(8):79. PubMed.
  8. . Advances in Management of Psychosis in Neurodegenerative Diseases. Curr Treat Options Neurol. 2019 Jan 23;21(1):3. PubMed.
  9. . Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. Parkinsonism Relat Disord. 2020 Aug;77:100-106. Epub 2020 Jun 28 PubMed.
  10. . Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer's disease: a systematic review. Int Clin Psychopharmacol. 2021 Jul 1;36(4):169-180. PubMed.